NO20064200L - Fremgangsmate for syntese av en CXCR4-antagonist - Google Patents
Fremgangsmate for syntese av en CXCR4-antagonistInfo
- Publication number
- NO20064200L NO20064200L NO20064200A NO20064200A NO20064200L NO 20064200 L NO20064200 L NO 20064200L NO 20064200 A NO20064200 A NO 20064200A NO 20064200 A NO20064200 A NO 20064200A NO 20064200 L NO20064200 L NO 20064200L
- Authority
- NO
- Norway
- Prior art keywords
- protected
- synthesis
- amine
- imine
- reacting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Foreliggende oppfinnelse angår fremgangsmåte for syntese av heterocykliske farmasøytiske forbindelser som bindes til CXCR4 chemokinreseptoren. I én utførelsesform, omfatter fremgangsmåten: a) omsetning av et 5,6,7,8-tetrahydrokinolinylamin og et alkylaldehyd som bærer en ftalimid eller en di-tertiær-butoksykarbonyl (di-BOC) beskyttelsesgruppe for å danne et imin; b) reduksjon av iminet for å danne et sekundært amin; c) omsetning av det sekundære aminet med en halogenalkyl substituert heterocyklisk forbindelse, for å danne et ftalimido-beskyttet eller di-tert-butoksykarbonyl beskyttet tertiær amin; og d) hydrolyse av det beskyttede aminet for å oppnå en forbindelse som har Formel I'
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55358904P | 2004-03-15 | 2004-03-15 | |
PCT/US2005/008268 WO2005090308A1 (en) | 2004-03-15 | 2005-03-11 | Process for the synthesis of a cxcr4 antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064200L true NO20064200L (no) | 2006-09-15 |
Family
ID=34993619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064200A NO20064200L (no) | 2004-03-15 | 2006-09-15 | Fremgangsmate for syntese av en CXCR4-antagonist |
Country Status (13)
Country | Link |
---|---|
US (1) | US7332605B2 (no) |
EP (1) | EP1730113B1 (no) |
JP (1) | JP4870660B2 (no) |
KR (1) | KR20060131899A (no) |
CN (1) | CN1930127B (no) |
AU (1) | AU2005224079A1 (no) |
BR (1) | BRPI0508703B8 (no) |
CA (1) | CA2558389C (no) |
ES (1) | ES2614508T3 (no) |
IL (1) | IL177511A (no) |
NO (1) | NO20064200L (no) |
RU (1) | RU2006136381A (no) |
WO (1) | WO2005090308A1 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
AU2005277638A1 (en) * | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
JP2009524689A (ja) * | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
EP1984376A4 (en) * | 2006-01-25 | 2009-04-08 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
US20100003224A1 (en) * | 2006-08-02 | 2010-01-07 | Genzyme Corporation | Combination Therapy |
EP2209766A1 (en) * | 2007-04-26 | 2010-07-28 | Dr. Reddy's Laboratories (EU) Limited | Novel aldehyde composition |
FR2934859B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
WO2012047538A1 (en) | 2010-10-06 | 2012-04-12 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
US10548889B1 (en) * | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
JP2023524522A (ja) | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | 抗covid-19剤としてのeタンパク質チャネル遮断薬およびorf3阻害剤 |
CA3233731A1 (en) * | 2021-10-07 | 2023-04-13 | Roger Hanselmann | Synthesis of mavorixafor and intermediates thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
CN1231215C (zh) * | 1997-06-02 | 2005-12-14 | 詹森药业有限公司 | (咪唑-5-基)甲基-2-喹啉酮衍生物用作平滑肌细胞增殖抑制剂 |
HUP0200761A3 (en) | 1999-03-24 | 2003-05-28 | Anormed Inc Langley | Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing them and their use |
ATE335733T1 (de) * | 2000-09-15 | 2006-09-15 | Anormed Inc | Chemokin rezeptor bindenden heterozyklischen verbindungen |
IL154227A0 (en) * | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
CZ10903U1 (en) * | 2001-01-11 | 2001-02-19 | Oldrich Ing Cihak | Bladed water wheel |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
KR20040068339A (ko) | 2001-12-21 | 2004-07-30 | 아노르메드 인코포레이티드 | 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물 |
-
2005
- 2005-03-11 CN CN2005800069769A patent/CN1930127B/zh active Active
- 2005-03-11 US US11/077,896 patent/US7332605B2/en active Active
- 2005-03-11 JP JP2007503981A patent/JP4870660B2/ja active Active
- 2005-03-11 CA CA2558389A patent/CA2558389C/en active Active
- 2005-03-11 ES ES05725450.0T patent/ES2614508T3/es active Active
- 2005-03-11 WO PCT/US2005/008268 patent/WO2005090308A1/en active Application Filing
- 2005-03-11 EP EP05725450.0A patent/EP1730113B1/en active Active
- 2005-03-11 RU RU2006136381/04A patent/RU2006136381A/ru not_active Application Discontinuation
- 2005-03-11 KR KR1020067019097A patent/KR20060131899A/ko not_active Application Discontinuation
- 2005-03-11 AU AU2005224079A patent/AU2005224079A1/en not_active Abandoned
- 2005-03-11 BR BRPI0508703A patent/BRPI0508703B8/pt active IP Right Grant
-
2006
- 2006-08-16 IL IL177511A patent/IL177511A/en active IP Right Grant
- 2006-09-15 NO NO20064200A patent/NO20064200L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1730113A4 (en) | 2009-12-02 |
IL177511A (en) | 2010-12-30 |
EP1730113B1 (en) | 2016-12-28 |
EP1730113A1 (en) | 2006-12-13 |
RU2006136381A (ru) | 2008-04-27 |
CA2558389A1 (en) | 2005-09-29 |
WO2005090308A1 (en) | 2005-09-29 |
KR20060131899A (ko) | 2006-12-20 |
AU2005224079A1 (en) | 2005-09-29 |
BRPI0508703B8 (pt) | 2021-05-25 |
CN1930127A (zh) | 2007-03-14 |
JP2007529526A (ja) | 2007-10-25 |
ES2614508T3 (es) | 2017-05-31 |
US20050209277A1 (en) | 2005-09-22 |
JP4870660B2 (ja) | 2012-02-08 |
IL177511A0 (en) | 2006-12-10 |
BRPI0508703A (pt) | 2007-08-07 |
CN1930127B (zh) | 2012-11-21 |
US7332605B2 (en) | 2008-02-19 |
BRPI0508703B1 (pt) | 2020-11-24 |
CA2558389C (en) | 2013-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064200L (no) | Fremgangsmate for syntese av en CXCR4-antagonist | |
ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
ATE449082T1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor | |
NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
DK1776377T3 (da) | Nyt steroid til FXR | |
DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
NO20076554L (no) | Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
CY1112402T1 (el) | Ενισχυτες υποδοχεων γλουταμικου | |
MY136959A (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
MX2009010552A (es) | Antagonistas de receptor de opioide periferico y usos de los mismos. | |
WO2008007113A3 (en) | Pharmaceutical combinations | |
MX2007009282A (es) | Nuevos procesos para la preparacion de un 2h-cromeno. | |
DE60235396D1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
GEP20084494B (en) | New heterocyclic carboxylic acid amide derivatives | |
NO20064175L (no) | Heterosyklisk forbindelse | |
NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
DE502006008710D1 (de) | Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament | |
NO20065789L (no) | Cinnamidforbindelse | |
MY140571A (en) | Mercaptoimidazoles as ccr2 receptor antagonists | |
ATE550326T1 (de) | Als modulatoren von hdl einsetzbare verbindungen | |
TW200606155A (en) | Mercaptoimidazoles as CCR2 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |